Bevonescein for Improved Intraoperative Nerve Visualization to Improve Voice Outcomes in Thyroidectomy Patients

Bevonescein (ALM-488) is a novel fluorescein-containing peptide that is intended as a visualization adjunct for the real-time enhanced structural delineation of major nerves during Head and Neck surgery to potentially improve patient outcomes.

Trial Details

NCT ID

NCT07631650

Phase

PHASE2

Sponsor

Matthew Spector

Status

RECRUITING

Cancer Type

Head and Neck Cancer

Interventions

Bevonescein (ALM 488) Infusion

Locations (sample)

Pittsburgh, Pennsylvania, United States|40.44062,-79.99589

Key Eligibility Criteria

Scheduled to undergo hemi thyroidectomy or total thyroidectomy for thyroid disease, including neoplasm
Must be a minimum of 18 years old or older
Must be able to give documented informed consent to participate in this study
Must be a surgical candidate according to standard of care practices, as determined by the clinical judgement of the investigator

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Head and Neck Cancer Trials on Trialify →